Source: European Journal Metabolism and Pharmacokinetics. Conference titles: European Congress of Biopharmaceutics and Pharmacokinetics. Unidades: FCF, FCFRP
Assunto: FARMACOLOGIA CLÍNICA
ABNT
SANTOS, S R C J et al. Reduction of hepatic oxidative drug metabolizing enzyme activities and conjugation capacity in liver cirrhosis and shistosomiasis. European Journal Metabolism and Pharmacokinetics. Geneva: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 10 nov. 2024. , 1996APA
Santos, S. R. C. J., Bertoline, M. A., Pereira, M. D., De Paula, M. A. S. A., Amosako, C., Donzella, H., & Lanchote, V. L. (1996). Reduction of hepatic oxidative drug metabolizing enzyme activities and conjugation capacity in liver cirrhosis and shistosomiasis. European Journal Metabolism and Pharmacokinetics. Geneva: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
Santos SRCJ, Bertoline MA, Pereira MD, De Paula MASA, Amosako C, Donzella H, Lanchote VL. Reduction of hepatic oxidative drug metabolizing enzyme activities and conjugation capacity in liver cirrhosis and shistosomiasis. European Journal Metabolism and Pharmacokinetics. 1996 ;(spec.): 76.[citado 2024 nov. 10 ]Vancouver
Santos SRCJ, Bertoline MA, Pereira MD, De Paula MASA, Amosako C, Donzella H, Lanchote VL. Reduction of hepatic oxidative drug metabolizing enzyme activities and conjugation capacity in liver cirrhosis and shistosomiasis. European Journal Metabolism and Pharmacokinetics. 1996 ;(spec.): 76.[citado 2024 nov. 10 ]